Double reoperations with osteosynthesis for femoral neck fracture vs. arthroplasty

A study presented at the American Academy of Orthopaedic Surgeons Annual Meeting compared health care utilization rates and reoperation rates in patients over 65 years old who underwent osteosynthesis versus arthroplasty for femoral neck fractures. The study found that the arthroplasty group had slightly higher 90-day health care utilization rates, but the osteosynthesis group had…

Read More

Beam, Prozac, “TechBio” and more

Biotech is thriving with a resurgence in psychiatric drug development and a two-year high for biotech stocks. The field of psychiatry is experiencing a renaissance with promising new medicines expected in 2024. Cytokinetics CEO confirms the company is not for sale but is open to partnership deals. Beam Therapeutics sees a surge in stock price…

Read More

Genetic risk tool could aid early diagnosis and treatment of multiple sclerosis patients

A new genetic risk tool could help diagnose multiple sclerosis (MS) earlier in young adults with optic neuritis, potentially preventing blindness. Optic neuritis is often a precursor to MS, and early treatment could improve long-term health outcomes. Research combining genetic risk for MS with demographic factors has shown promise in predicting MS risk in individuals…

Read More

Baby Development Stages: The First Year

Babies undergo incredible transformation in the first year of life, reaching important developmental milestones at their own pace. The first three months are characterized by smiling, head control, and hand-eye coordination. Between 4 and 6 months, babies start babbling, laughing, and reaching for objects. The next stage, from 7 to 9 months, sees babies crawling,…

Read More

Health Bulletin 28/ February/ 2024

This health bulletin from February 28, 2024, states that cookies are used on the website for analytics, advertising, and site improvement. By continuing to use the site, users agree to the use of cookies. More information can be found in the Cookie Policy and Cookie Settings. Source link

Read More

Janux Rides Its TRACTr to Validation in Prostate Cancer and More Solid Tumors

Janux Therapeutics is developing T cell engagers to treat tumors, with promising Phase 1 data showing potential for blockbuster success. Their technology, TRACTr, aims to overcome limitations of current therapies by reducing toxicity and increasing efficacy. Their lead program, JANX007, has shown positive results in treating prostate cancer, with significant declines in PSA levels without…

Read More